Ngā hua rapu - Josep M. Piulats
- E whakaatu ana i te 1 - 20 hua o te 52
- Haere ki te Whārangi Whai Ake
-
1
Uveal melanoma as a target for immune-therapy mā Marc Oliva, Antonio Rullan, Josep M. Piulats
I whakaputaina 2016Revisão -
2
Facts and Hopes in Immunotherapy of Endometrial Cancer mā Juan A. Marín‐Jiménez, Sandra García‐Mulero, Xavier Matías‐Guiu, Josep M. Piulats
I whakaputaina 2022Revisão -
3
-
4
A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations mā David Tamborero, Carlota Rubio-Pérez, Ferran Muiños, Radhakrishnan Sabarinathan, Josep M. Piulats, Aura Muntasell, Rodrigo Dienstmann, Núria López-Bigas, Abel González-Pérez
I whakaputaina 2018Artigo -
5
Lung metastases share common immune features regardless of primary tumor origin mā Sandra García‐Mulero, M. Henar Alonso, Julián Pardo, Cristina Santos, Xavier Sanjuán, Ramón Salazar, Vı́ctor Moreno, Josep M. Piulats, Rebeca Sanz‐Pamplona
I whakaputaina 2020Artigo -
6
Dynamic Change of Polarity in Primary Cultured Spheroids of Human Colorectal Adenocarcinoma and Its Role in Metastasis mā Hiroaki Okuyama, Jumpei Kondo, Yumi Sato, Hiroko Endo, Aya Nakajima, Josep M. Piulats, Yasuhiko Tomita, Takeshi Fujiwara, Yu Itoh, Akira Mizoguchi, Masayuki Ohue, Masahiro Inoue
I whakaputaina 2016Artigo -
7
Sunitinib Inhibits Tumor Growth and Synergizes with Cisplatin in Orthotopic Models of Cisplatin-Sensitive and Cisplatin-Resistant Human Testicular Germ Cell Tumors mā Wilmar Castillo, Josep M. Piulats, Xavier García del Muro, August Vidal, Enric Condom, Oriol Casanovas, Josefina Móra, Josep R. Germà, Gabriel Capellà, Alberto Villanueva, Francesc Viñals
I whakaputaina 2009Artigo -
8
A Phase 1 Trial of Oncolytic Adenovirus ICOVIR-5 Administered Intravenously to Cutaneous and Uveal Melanoma Patients mā Margarita García, Rafael Moreno, Marta Gil-Martín, Manel Cascalló, María Ochoa de Olza, C. Cuadra, Josep M. Piulats, Valentín Navarro, Marta Domènech, Ramón Alemany, Ramón Salazar
I whakaputaina 2018Artigo -
9
KEYNOTE-921: Phase III Study of Pembrolizumab Plus Docetaxel for Metastatic Castration-Resistant Prostate Cancer mā Daniel P. Petrylak, Raffaele Ratta, Rustem Gafanov, Gaetano Facchini, Josep M. Piulats, Gero Kramer, Thomas W. Flaig, Sreenivasa R Chandana, Ben Li, Joseph E. Burgents, Karim Fizazi
I whakaputaina 2021Artigo -
10
Chemotherapy As an Alternative to Radiotherapy in the Treatment of Stage IIA and IIB Testicular Seminoma: A Spanish Germ Cell Cancer Group Study mā Xavier García del Muro, Pablo Maroto, Josep Gumà, Javier Sastre, Marta López Brea, José Ángel Arranz, Núria Laínez, Diego Soto de Prado, Jorge Aparicio, Josep M. Piulats, Xavier Pérez, Josep Ramón Germà-Lluch
I whakaputaina 2008Artigo -
11
Pembrolizumab Monotherapy for Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Arm Phase II Trial (KEYNOTE-629) mā Jean‐Jacques Grob, René González, Nicole Basset‐Séguin, Olga Vornicova, Jacob Schachter, Abhishek Joshi, Nicolás Meyer, Florent Grange, Josep M. Piulats, Jessica R. Bauman, Pingye Zhang, Burak Gümüşçü, Ramona F. Swaby, Brett Hughes
I whakaputaina 2020Artigo -
12
Phase II Randomized Study of Figitumumab plus Docetaxel and Docetaxel Alone with Crossover for Metastatic Castration-Resistant Prostate Cancer mā Johann S. de Bono, Josep M. Piulats, Hardev Pandha, Daniel P. Petrylak, Fred Saad, Luis M. Antón Aparicio, Shahneen Sandhu, Peter C.C. Fong, Silke Gillessen, Gary R. Hudes, Tao Wang, J. R. Scranton, Michaël Pollak
I whakaputaina 2014Artigo -
13
A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive, metastatic, castration-resistant prostate cancer mā Teresa Alonso‐Gordoa, Michael Goodman, Christof Vulsteke, Guilhem Roubaud, J. Zhang, Mamta Parikh, Josep M. Piulats, A. Ázaro, Gary D. James, Riccardo Cavazzina, Eric T. Gangl, Jeff Thompson, Gayle P. Pouliot, Rakesh Kumar, Christopher J. Sweeney
I whakaputaina 2024Artigo -
14
AURKA Overexpression Is Driven by FOXM1 and MAPK/ERK Activation in Melanoma Cells Harboring BRAF or NRAS Mutations: Impact on Melanoma Prognosis and Therapy mā Joan Anton Puig‐Butillé, Antònia Vinyals, J.R. Ferreres, Paula Aguilera, Eduard Cabré, Gemma Tell‐Martí, Joaquim Marcoval, Francesca Mateo, Luís Palomero, Célia Bádenas, Josep M. Piulats, Josep Malvehy, Miguel Ángel Pujana, Susana Puig, Àngels Fabra
I whakaputaina 2017Artigo -
15
Sensitivity of cervico‐vaginal cytology in endometrial carcinoma: A systematic review and meta‐analysis mā Jon Frias‐Gomez, Yolanda Benavente, Jordi Ponce, Joan Brunet, Raquel Ibáñez, Paula Peremiquel‐Trillas, Núria Baixeras, Alba Zanca, Josep M. Piulats, Àlvaro Aytés, Xavier Matías‐Guiu, F. Xavier Bosch, Sílvia de Sanjosé, Laia Alemany, Laura Costas
I whakaputaina 2020Revisão -
16
Epigenetic disruption of cadherin‐11 in human cancer metastasis mā F. Javier Carmona, Alberto Villanueva, August Vidal, Clara Muñoz, Sara Puertas, R.M. Penín, Montserrat Gomà‐i‐Freixanet, Amaia Lujambio, Josep M. Piulats, Ricard Mesı́a, Montse Sánchez‐Céspedes, M. Mañós, Enric Condom, Suzanne A. Eccles, Manel Esteller
I whakaputaina 2012Artigo -
17
1,4-dihydroxy quininib activates ferroptosis pathways in metastatic uveal melanoma and reveals a novel prognostic biomarker signature mā Valentina Tonelotto, Marcel Costa-García, Eve O’Reilly, Kaelin Francis Smith, Kayleigh Slater, Eugène Dillon, Marzia Pendino, Catherine Higgins, Paola Sist, Rosa Bosch, Sabina Passamonti, Josep M. Piulats, Alberto Villanueva, Federica Tramer, Luca Vanella, Michelle Carey, Breandán N. Kennedy
I whakaputaina 2024Artigo -
18
ERA 223: A phase III trial of radium-223 (Ra-223) in combination with abiraterone acetate and prednisone/prednisolone for the treatment of asymptomatic or mildly symptomatic chemot... mā Mitchell R. Smith, Chris Parker, Fred Saad, K. Miller, Bertrand Tombal, Quan Sing Ng, Martin Bögemann, В. Б. Матвеев, Josep M. Piulats, Luis Eduardo Rosa Zucca, Axel Heidenreich, Yoshiyuki Kakehi, A. Zhang, Heiko Krissel, Jiayu Shen, V. Wagner, Celestia S. Higano
I whakaputaina 2018Artigo -
19
Nivolumab Plus Ipilimumab for Treatment-Naïve Metastatic Uveal Melanoma: An Open-Label, Multicenter, Phase II Trial by the Spanish Multidisciplinary Melanoma Group (GEM-1402) mā Josep M. Piulats, Enrique Espinosa, Luis de la Cruz‐Merino, Mar Varela, Lorenzo Alonso-Carrión, Salvador Martín‐Algarra, Rafael López Castro, Teresa Curiel, Delvys Rodríguez‐Abreu, Miriam Redrado, Montserrat Gomà‐i‐Freixanet, Antonio Rullan, Alfonso Calvo González, Alfonso Berrocal-Jaime
I whakaputaina 2021Artigo -
20
Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis mā Josep M. Piulats, Claire Watkins, Marcel Costa-García, L. Del Carpio, Sophie Piperno‐Neumann, Piotr Rutkowski, Jessica C. Hassel, Enrique Espinosa, Luis de la Cruz‐Merino, Sebastian Ochsenreither, A.N. Shoushtari, Marlana Orloff, April K.S. Salama, Howard Goodall, Jean‐François Baurain, Paul Nathan
I whakaputaina 2023Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Medicine
Cancer
Internal medicine
Cancer research
Oncology
Biology
Gene
Genetics
Immunotherapy
Melanoma
Prostate cancer
Surgery
Immunology
Chemotherapy
Clinical endpoint
Clinical trial
Gastroenterology
Pembrolizumab
Biochemistry
Immune system
Pathology
Urology
Adverse effect
Confidence interval
Androgen deprivation therapy
Androgen receptor
Cell biology
Chemistry
Enzalutamide
Germ cell tumors